Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 2, 2008, Pages 223-229

  O'Kane, Peter D ^a,b   Reebye, Vikash ^a   Ji, Yong ^a   Stratton, Paula ^a   Jackson, Graham ^b   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Beta adrenoceptors; Clopidogrel; Nitric oxide; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARGININE; BETA 2 ADRENERGIC RECEPTOR; CITRULLINE; CLOPIDOGREL; COLLAGEN; CYCLIC GMP; ISOPRENALINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SALBUTAMOL; THROMBIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOGENESIS; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ASPIRIN; BLOOD PLATELETS; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; TICLOPIDINE;

EID: 48849091036     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.05.015     Document Type: Article

References (33)

1. Gkaliagkousi E., Ritter J., and Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ. Res. 101 (2007) 654-662
2. 2-Adrenoceptors activate nitric oxide synthase in human platelets. Circ. Res. 87 (2000) 39-44
3. Diodati J.G., Dakak N., Gilligan D.M., and Quyyumi A.A. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98 (1998) 17-24
4. Freedman J.E., Ting B., Hankin B., Loscalzo J., Keaney Jr. J.F., and Vita J.A. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98 (1998) 1481-1486
5. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56 (1975) 624-632
6. Chen L., Salafranca M.N., and Mehta J.L. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am. J. Physiol. 273 (1997) H1854-H1859
7. O'Kane P.D., Queen L.R., Ji Y., Reebye V., Stratton P., Jackson G., et al. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc. Res. 59 (2003) 152-159
8. Galla J.M., and Lincoff A.M. The role of clopidogrel in the management of ischemic heart disease. Curr. Opin. Cardiol. 22 (2007) 273-279
9. Riba R., Oberprieler N.G., Roberts W., and Naseem K.M. Von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib-dependent mechanism. J. Thromb. Haemost. 4 (2006) 2636-2644
10. Yin H., Stojanovic A., Hay N., and Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 111 (2008) 658-665
11. Li Z., Zhang G., Le Breton G.C., Gao X., Malik A.B., and Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J. Biol. Chem. 278 (2003) 30725-30731
12. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
13. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
14. Goubareva I., Gkaliagkousi E., Shah A., Queen L., Ritter J., and Ferro A. Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates. Cardiovasc. Res. 75 (2007) 793-802
15. Xu B., Chibber R., Ruggiero D., Kohner E., Ritter J., and Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 17 (2003) 1289-1291
16. Waldmann R., Nieberding M., and Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur. J. Biochem. 167 (1987) 441-448
17. Butt E., Abel K., Krieger M., Palm D., Hoppe V., and Walter U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269 (1994) 14509-14517
18. Zhao L., Gray L., Leonardi-Bee J., Weaver C.S., Heptinstall S., and Bath P.M. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 17 (2006) 100-104
19. Heitzer T., Rudolph V., Schwedhelm E., Karstens M., Sydow K., Ortak M., et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1648-1652
20. Jakubowski A., Chlopicki S., Olszanecki R., Jawien J., Lomnicka M., Dupin J.P., et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 139-145
21. Kanko M., Ozden M., Maral H., and Acil C. Effect of clopidogrel on nitric oxide levels in an ischemia reperfusion model. J. Cardiovasc. Pharmacol. 48 (2006) 797-801
22. Communi D., Govaerts C., Parmentier M., and Boeynaems J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272 (1997) 31969-31973
23. i. J. Biol. Chem. 276 (2001) 41479-41485
24. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
25. Storey R.F., and Heptinstall S. Laboratory investigation of platelet function. Clin. Lab. Haematol. 21 (1999) 317-329
26. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., and Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104 (2001) 1533-1537
27. Celi A., Pellegrini G., Lorenzet R., De Blasi A., Ready N., Furie B.C., et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8767-8771
28. Dong Z.M., Brown A.A., and Wagner D.D. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 101 (2000) 2290-2295
29. Cao Y.J., Wang Y.M., Zhang J., Zeng Y.J., and Liu C.F. The effects of antiplatelet agents on platelet-leukocyte aggregations in patients with acute cerebral infarction. J. Thromb. Thrombolysis. (2008 Jan 11) [Epub ahead of print]
30. Graff J., Harder S., Wahl O., Scheuermann E.H., and Gossmann J. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin. Pharmacol. Ther. 78 (2005) 468-476
31. Klinkhardt U., Graff J., and Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin. Pharmacol. Ther. 71 (2002) 176-185
32. Klinkhardt U., Bauersachs R., Adams J., Graff J., Lindhoff-Last E., and Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin. Pharmacol. Ther. 73 (2003) 232-241
33. Klinkhardt U., and Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?. Semin. Thromb. Hemost. 31 (2005) 400-403